DNLI Denali Therapeutics Inc. Stock Quote

DNLI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.21	Insider Own	0.40%	Shs Outstand	107.49M	Perf Week	9.99%
Market Cap	8.35B	Forward P/E	-	EPS next Y	-1.96	Insider Trans	-85.45%	Shs Float	98.80M	Perf Month	2.97%
Income	-227.80M	PEG	-	EPS next Q	0.01	Inst Own	87.60%	Short Float	7.06%	Perf Quarter	17.67%
Sales	23.50M	P/S	355.46	EPS this Y	-428.30%	Inst Trans	11.56%	Short Ratio	10.37	Perf Half Y	121.20%
Book/sh	8.21	P/B	8.75	EPS next Y	-24.80%	ROA	-30.70%	Target Price	78.78	Perf Year	277.50%
Cash/sh	8.26	P/C	8.69	EPS next 5Y	-	ROE	-39.20%	52W Range	12.39 - 93.94	Perf YTD	-14.28%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-53.90%	52W High	-23.57%	Beta	-
Dividend %	-	Quick Ratio	9.20	Sales past 5Y	-	Gross Margin	-	52W Low	479.50%	ATR	5.28
Employees	281	Current Ratio	9.20	Sales Q/Q	-30.90%	Oper. Margin	-	RSI (14)	53.26	Volatility	8.85% 7.24%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-12.30%	Profit Margin	-	Rel Volume	1.48	Prev Close	63.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	672.85K	Price	71.80
Recom	2.20	SMA20	5.13%	SMA50	-4.31%	SMA200	53.99%	Volume	993,966	Change	13.97%

Feb-26-21

Reiterated

H.C. Wainwright

Buy

$80 → $95

Feb-10-21

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$105

Nov-11-20

Reiterated

H.C. Wainwright

Buy

$65 → $80

Oct-16-20

Downgrade

BTIG Research

Buy → Neutral

Sep-14-20

Resumed

JP Morgan

Overweight

$35

Aug-20-20

Reiterated

H.C. Wainwright

Buy

$28 → $45

Mar-13-20

Upgrade

Evercore ISI

In-line → Outperform

$20

Feb-28-20

Upgrade

Wedbush

Neutral → Outperform

$24

Feb-24-20

Initiated

Jefferies

Buy

$35

Feb-19-20

Initiated

Stifel

Hold

$26

Jan-27-20

Upgrade

Goldman

Neutral → Buy

$20 → $37

Sep-26-19

Initiated

Wedbush

Neutral

$19

Sep-13-19

Initiated

Nomura

Buy

Aug-09-19

Initiated

BTIG Research

Buy

$30

Jun-26-19

Initiated

H.C. Wainwright

Buy

$28

Nov-15-18

Initiated

Cantor Fitzgerald

Overweight

$25

Nov-12-18

Initiated

Janney

Buy

Mar-12-18

Downgrade

Evercore ISI

Outperform → In-line

Jan-02-18

Initiated

Morgan Stanley

Overweight

Jan-02-18

Initiated

JP Morgan

Overweight

$24

Feb-25-21 04:01PM	Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights GlobeNewswire -5.63%
Feb-16-21 04:16PM	Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs? Investor's Business Daily -6.03%
Feb-12-21 08:54AM	Denali's Enzyme Replacement Therapy Shows Encouraging Biomarker Effects In Early-Stage Hunter Syndrome Study Benzinga
07:30AM	Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II) GlobeNewswire
Feb-11-21 01:27AM	We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely Simply Wall St. -5.32%
Feb-05-21 09:00AM	Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium GlobeNewswire
Jan-11-21 08:30AM	Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors GlobeNewswire
Jan-08-21 08:30AM	Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration GlobeNewswire +8.32%
Dec-23-20 03:33PM	Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today Motley Fool -5.87%
Dec-22-20 09:48AM	5 Medical Outperformers That Might Lose Steam in 2021 Zacks
Nov-18-20 09:36AM	3 Best Biotech Stocks to Buy in November Motley Fool -6.91%
Nov-13-20 08:35AM	Denali Therapeutics (DNLI) Surges: Stock Moves 5.7% Higher Zacks -6.82%
06:06AM	Industry Analysts Just Made A Massive Upgrade To Their Denali Therapeutics Inc. (NASDAQ:DNLI) Revenue Forecasts Simply Wall St.
Nov-12-20 11:18AM	Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals? Motley Fool +5.70%
Nov-10-20 07:30AM	Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II) GlobeNewswire +7.51%
Nov-05-20 04:01PM	Denali Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Oct-21-20 02:00PM	Biogen Inc (BIIB) Q3 2020 Earnings Call Transcript Motley Fool
Oct-18-20 11:00AM	Goldman Sachs: 2 Stocks That Could Climb Over 90% TipRanks
Oct-15-20 08:00AM	Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today GlobeNewswire
Oct-07-20 08:30AM	Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen GlobeNewswire
Oct-05-20 12:01PM	Hedge Funds Are Crazy About Denali Therapeutics Inc. (DNLI) Insider Monkey
Sep-30-20 09:00AM	Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier GlobeNewswire
Sep-24-20 11:46AM	25 Easiest Trivia Questions For Seniors With Dementia Insider Monkey
Aug-18-20 11:37AM	Loss-Making Denali Therapeutics Inc. (NASDAQ:DNLI) Set To Breakeven Simply Wall St.
Aug-07-20 05:45PM	Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:30PM	Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Aug-06-20 04:19PM	Biogen, Denali Announce Billion-Dollar Collaboration On Parkinson's Treatment Investor's Business Daily +36.23%
09:13AM	Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration MarketWatch
08:07AM	Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinsons Patients GlobeNewswire
Jul-29-20 09:00AM	Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients GlobeNewswire
Jul-28-20 12:32PM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-07-20 08:00AM	Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing PR Newswire
Jun-28-20 07:06PM	Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI) Insider Monkey
Jun-10-20 02:03PM	Sanofi and Denali Halt Clinical Trials of Alzheimer Drug Motley Fool
02:51AM	Denali Drops 7% In After-Market On Halt Of DNL747 Drug Study SmarterAnalyst
Jun-09-20 04:30PM	Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi GlobeNewswire
May-28-20 11:21AM	Venture Funding of Drug Startups Down, But Not Out GuruFocus.com
08:00AM	Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity PR Newswire
May-27-20 04:30PM	Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine GlobeNewswire +5.67%
May-21-20 12:00PM	What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock Zacks
May-10-20 09:18AM	Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report Simply Wall St.
May-07-20 08:20PM	Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.58%
04:30PM	Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update GlobeNewswire
May-06-20 12:30PM	Analysts Estimate Denali Therapeutics Inc.(DNLI) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-15-20 02:49PM	Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock? Insider Monkey
Apr-09-20 06:08PM	Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals
Apr-02-20 04:30PM	Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic GlobeNewswire +8.93%
Feb-29-20 08:47AM	Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Feb-27-20 05:55PM	Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates Zacks -12.07%
04:30PM	Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights GlobeNewswire
Feb-17-20 10:06AM	3 Stocks That Are Way More Expensive Than Tesla GuruFocus.com
Feb-14-20 03:00PM	Denali Therapeutics chief medical officer sets a cultural standard American City Business Journals
12:00PM	Denali Therapeutics Inc. (DNLI) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Feb-07-20 11:30AM	Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year? Zacks
Feb-03-20 11:11AM	Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks
Jan-31-20 08:42PM	Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
03:02PM	Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales Zacks
09:52AM	Moving Average Crossover Alert: Denali Therapeutics Zacks
Jan-30-20 11:10AM	Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks -6.81%
10:54AM	Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% TipRanks
10:15AM	Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Jan-29-20 11:11AM	Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal Zacks
10:06AM	Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation Zacks
Jan-28-20 08:58PM	Denali Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.22%
11:14AM	AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study Zacks
Jan-27-20 04:10PM	Denali Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire +13.51%
Jan-23-20 09:34AM	Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks +6.41%
Jan-22-20 10:00AM	Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks +6.32%
Jan-16-20 09:52AM	Novavax Rises on Fast Track Designation to Influenza Vaccine Zacks +7.41%
Jan-15-20 09:36AM	Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results Zacks -9.48%
06:11AM	Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-14-20 10:03AM	Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View Zacks +29.35%
09:00AM	Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinsons Disease GlobeNewswire
Dec-31-19 11:01AM	Denali Therapeutics (NASDAQ:DNLI) Is In A Strong Position To Grow Its Business Simply Wall St.
Dec-19-19 08:00AM	Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire +8.11%
Dec-17-19 04:06PM	Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-19 08:58AM	Options Traders Expect Huge Moves in Denali (DNLI) Stock Zacks
Nov-06-19 07:25PM	Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:30PM	Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights GlobeNewswire
Oct-27-19 11:08AM	Were Hedge Funds Right About Ditching Denali Therapeutics Inc. (DNLI)? Insider Monkey
Sep-04-19 09:00AM	Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinsons Disease and Launch of Its Engage Parkinsons Website GlobeNewswire
Aug-06-19 08:05PM	Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:30PM	Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights GlobeNewswire
Aug-05-19 09:00AM	Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study GlobeNewswire
Aug-01-19 10:33AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-04-19 06:03AM	Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company? Simply Wall St.
Jun-29-19 06:27PM	Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI) Insider Monkey
Jun-12-19 10:30AM	Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks
Jun-11-19 09:00AM	Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs GlobeNewswire
May-08-19 08:05PM	Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:30PM	Denali Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-03-19 10:30AM	Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for Zacks
May-01-19 05:43PM	Controversial Alzheimer's Disease theory could pinpoint new drug targets American City Business Journals
Apr-30-19 02:52PM	Heres What Hedge Funds Think About Denali Therapeutics Inc. (DNLI) Insider Monkey
Apr-15-19 03:00PM	Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals
Apr-10-19 10:03AM	3 Biotech Stocks That Doubled After Hitting Bottom in 2018 Motley Fool
Apr-02-19 02:46PM	Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%? Simply Wall St. +6.30%
Mar-14-19 02:42PM	Harry Boxers 4 stocks running on earnings MarketWatch
Mar-12-19 10:35AM	Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates Zacks
09:00AM	Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights GlobeNewswire

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krognes Steve E.	CFO and Treasurer	Feb 16	Sale	65.09	50,000	3,254,710	900,000	Feb 18 06:12 PM
BRATTON DOUGLAS K	10% Owner	Feb 12	Sale	65.00	2,216,798	144,091,870	9,984,836	Feb 17 08:39 PM
Ho Carole	Chief Medical Officer	Feb 11	Sale	70.33	3,156	221,972	172,233	Feb 16 07:43 PM
Schuth Alexander O.	COO and Secretary	Feb 11	Sale	70.35	3,047	214,341	541,582	Feb 16 07:43 PM
Krognes Steve E.	CFO and Treasurer	Feb 11	Sale	70.34	3,035	213,480	97,587	Feb 16 07:42 PM
Watts Ryan J.	President and CEO	Feb 11	Sale	70.30	9,473	665,984	2,324,076	Feb 16 07:40 PM
Ho Carole	Chief Medical Officer	Feb 09	Sale	74.68	1,470	109,785	167,921	Feb 11 07:10 PM
Krognes Steve E.	CFO and Treasurer	Feb 09	Sale	74.68	1,448	108,135	12,979	Feb 11 07:11 PM
Schuth Alexander O.	COO and Secretary	Feb 09	Sale	74.80	1,468	109,809	537,344	Feb 11 07:13 PM
Watts Ryan J.	President and CEO	Feb 09	Sale	73.79	5,112	377,211	2,313,853	Feb 10 07:40 PM
Watts Ryan J.	President and CEO	Feb 08	Option Exercise	0.00	14,316	0	2,318,965	Feb 10 07:40 PM
Schuth Alexander O.	COO and Secretary	Feb 07	Option Exercise	0.00	4,250	0	538,812	Feb 11 07:13 PM
Krognes Steve E.	CFO and Treasurer	Feb 07	Option Exercise	0.00	4,250	0	14,427	Feb 11 07:11 PM
Ho Carole	Chief Medical Officer	Feb 07	Option Exercise	0.00	4,250	0	169,391	Feb 11 07:10 PM
Schuth Alexander O.	COO and Secretary	Feb 04	Sale	67.84	10,000	678,361	534,562	Feb 05 04:44 PM
Watts Ryan J.	President and CEO	Feb 01	Sale	68.44	18,334	1,254,819	2,304,649	Feb 02 09:21 PM
Krognes Steve E.	CFO and Treasurer	Jan 15	Sale	71.45	50,000	3,572,556	950,000	Jan 20 06:46 PM
Schuth Alexander O.	COO and Secretary	Jan 04	Sale	74.95	70,000	5,246,408	544,562	Jan 06 06:50 PM
Watts Ryan J.	President and CEO	Jan 04	Sale	74.96	88,334	6,621,782	2,322,978	Jan 06 06:49 PM
Schenkein David P	Director	Dec 21	Sale	90.01	5,000	450,027	26,232	Dec 23 09:52 PM
Schenkein David P	Director	Dec 21	Sale	90.06	25,000	2,251,555	0	Dec 23 09:52 PM
BRATTON DOUGLAS K	10% Owner	Dec 14	Sale	80.38	17,825	1,432,842	383,411	Dec 15 04:47 PM
BRATTON DOUGLAS K	10% Owner	Dec 11	Sale	80.05	46,799	3,746,442	401,236	Dec 15 04:47 PM
Schenkein David P	Director	Nov 12	Sale	70.05	30,000	2,101,590	25,000	Nov 13 05:13 PM
Schenkein David P	Director	Nov 10	Sale	60.03	10,000	600,310	55,000	Nov 12 04:21 PM
Schenkein David P	Director	Nov 04	Sale	50.18	10,000	501,830	65,000	Nov 06 05:53 PM
Ho Carole	Chief Medical Officer	Oct 09	Option Exercise	5.28	30,000	158,400	196,617	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Oct 09	Sale	41.22	30,000	1,236,614	166,617	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Oct 08	Option Exercise	5.28	22,906	120,944	189,523	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Oct 08	Sale	40.12	22,906	918,989	166,617	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Sep 10	Sale	31.00	3,689	114,359	165,141	Sep 14 09:38 PM
BRATTON DOUGLAS K	10% Owner	Aug 12	Sale	31.65	1,443,247	45,678,768	12,201,634	Aug 14 04:50 PM
BRATTON DOUGLAS K	10% Owner	Jun 30	Sale	24.01	45,345	1,088,601	448,035	Jun 30 07:17 PM
BRATTON DOUGLAS K	10% Owner	Jun 29	Sale	24.01	82,578	1,982,373	493,380	Jun 30 07:17 PM
BRATTON DOUGLAS K	10% Owner	Jun 26	Sale	23.94	122,077	2,922,078	575,958	Jun 30 07:17 PM
BRATTON DOUGLAS K	10% Owner	Jun 23	Sale	25.77	20,024	515,969	698,035	Jun 23 05:41 PM
BRATTON DOUGLAS K	10% Owner	Jun 22	Sale	24.78	90,056	2,231,902	718,059	Jun 23 05:41 PM
BRATTON DOUGLAS K	10% Owner	Jun 19	Sale	24.54	144,920	3,556,503	808,115	Jun 23 05:41 PM
Tessier-Lavigne Marc	Director	Jun 16	Sale	26.10	400,000	10,440,000	2,739,043	Jun 18 09:41 PM
BRATTON DOUGLAS K	10% Owner	Jun 05	Sale	25.75	1,922,855	49,513,516	13,644,881	Jun 09 04:10 PM
Krognes Steve E.	CFO and Treasurer	Mar 30	Sale	19.48	1,428	27,817	1,006,488	Apr 01 06:19 PM
Schuth Alexander O.	COO and Secretary	Mar 30	Sale	19.49	1,427	27,812	28,662	Apr 01 06:19 PM
Watts Ryan J.	President and CEO	Mar 30	Sale	19.48	4,807	93,640	22,013	Apr 01 06:17 PM
Ho Carole	Chief Medical Officer	Mar 30	Sale	19.48	1,428	27,817	2,822	Apr 01 06:18 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience